An Interindividual Comparison of O-(2- [18F]Fluoroethyl)-L-Tyrosine (FET)– and L-[Methyl-11C]Methionine (MET)–PET in Patients With Brain Gliomas and Metastases

Grosu, Anca‐Ligia; Astner, Sabrina T.; Riedel, Eva; Nieder, Carsten; Wiedenmann, Nicole; Heinemann, F.; Schwaiger, Markus; Molls, M.; Wester, Hans‐Jürgen; Weber, Wolfgang

doi:10.1016/j.ijrobp.2010.07.002

Cited by 224 publications

(188 citation statements)

References 25 publications

Supporting

Mentioning

175

Contrasting

Unclassified

Order By: Relevance

“…For example, it has been demonstrated that dynamic 18 F-FET PET parameters have a high prognostic value in newly diagnosed low-and high-grade glioma (14,15). In secondary cerebral neoplasms, a few PET studies on pretreated brain metastases are currently available and have assessed the value of amino acid PET for the differentiation of recurrent disease from radiation-induced changes after radiotherapy (13,(16)(17)(18)(19). A recent study compared the tumor volume of partly untreated brain metastases in 18 F-FET PET and MRI, but there were criticisms regarding the methodology of that study (20,21).…”

mentioning

confidence: 99%

¹⁸F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis

Galldiks

Suchorska

Kowalew³

et al. 2016

J Nucl Med

View full text Add to dashboard Cite

In patients with brain metastasis, PET using labeled amino acids has gained clinical importance, mainly regarding the differentiation of viable tumor tissue from treatment-related effects. However, there is still limited knowledge concerning the uptake characteristics in patients with newly diagnosed and untreated brain metastases. Hence, we evaluated the uptake characteristics in these patients using dynamic . In 39 of 45 brain metastases eligible for dynamic analysis, a wide range of TTP min was observed (median, 22.5 min; range, 4.5-47.5 min). All 18 F-FETnegative metastases had a diameter of # 1.0 cm, whereas metastases with a . 1.0 cm diameter all showed pathologic 18 F-FET uptake, which did not correlate with lesion size. The highest variability of uptake intensity was observed within the group of melanoma metastases. Conclusion: Untreated metastases predominantly show increased 18 F-FET uptake, and only a third of metastases , 1.0 cm were 18 F-FET-negative, most likely because of scanner resolution and partial-volume effects. In metastases . 1.0 cm, 18 F-FET uptake intensity was highly variable and independent of tumor size (even intraindividually). 18 F-FET PET might provide additional information beyond the tumor extent by reflecting molecular features of a metastasis and might be a useful tool for future clinical applications, for example, response assessment. Br ain metastases are secondary intracerebral neoplasms and occur in up to 17% of all cancer patients. Because of the improved treatment options for extracranial primary tumors with consecutive prolonged survival, the incidence of brain metastases is expected to increase. The most common originating primary tumors are lung cancer, breast cancer, and malignant melanoma (in sum up to 80% of all metastases) (1).Systemic treatment usually consists of chemotherapy, immunotherapies, and targeted therapy, which, however, are mostly unable to cross the blood-brain barrier (BBB) (2,3). In brain metastases, treatment options such as whole resection, whole-brain radiation therapy, external fractionated radiotherapy, radiosurgery, and brachytherapy (4,5) are frequently used; additionally, recent experimental developments are heading toward new immunotherapies being able to cross the BBB (6).Currently, contrast-enhanced standard MRI represents the diagnostic gold standard in the clinical management of patients with brain metastases (7). However, the diagnostic performance of this technique is limited regarding the differentiation between primary and secondary intracerebral malignancies, tumor delineation, differentiation of recurrent brain metastasis from posttherapeutic effects, and providing prognostic information in newly diagnosed brain tumors (8,9). Thus, there is an increasing demand for additional imaging options.Regarding the diagnostic evaluation of intracerebral neoplasms, molecular imaging using PET has gained great importance. Particularly, radiolabeled amino acids such as O-(2-18 F-fluoroethyl)-L-tyrosine ( 18 F-FET) were reported to be particula...

show abstract

mentioning

confidence: 99%

¹⁸F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis

Galldiks

Suchorska

Kowalew³

et al. 2016

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…The LNR of 11 C-MET PET revealed a sensitivity and specificity of 70-80% for the differentiation of brain metastasis recurrence from radiation-related effects (31). A higher diagnostic accuracy was shown by Grosu et al, with 11 C-MET able to differentiate tumor tissue from treatment-related changes with a sensitivity of 91% and a specificity of 100% (63). Using 18 F-FET PET, the detection of tumor recurrence/progression was even more accurate, with a sensitivity and specificity of 100% and 93%, respectively, compared with 93-and 50% for MRI alone (73,78).…”

Section: Amino-acid Petmentioning

confidence: 90%

PET for Therapy Response Assessment in Glioblastoma

et al. 2017

View full text Add to dashboard Cite

Glioblastoma (GB) is the most malignant and the most common type of glioma in adults, accounting for 60-70% of all malignant gliomas. Despite the current therapy, the clinical course of GB is usually rapid, with a mean survival time of approximately 1 year. For therapy response assessment in GB, magnetic resonance imaging (MRI) is the method of choice. In 2010, the Response Assessment in Neuro-Oncology (RANO) was introduced, including the tumor size (in 2D) as measured on T2-weighted and Fluid Attenuated Inversion Recovery (FLAIR)-weighted images, in addition to the contrast-enhancing tumor part. Although the RANO criteria addressed some of the limitations of the previous MacDonald criteria for therapy evaluation in high-grade glioma, treatment-related side effects hamper correct response assessment. To address the above-mentioned drawbacks in the follow-up of GB, incorporating changes in tumor biology measured by advanced MRI and positron emission tomography (PET) imaging, which may precede anatomical changes of the tumor volume, is promising. Imaging biomarkers capable of predicting response at an early time point after treatment initiation are the premise of personalized treatment enabling change or GB Treatment Response Using PET 176 discontinuation of therapy to prevent ineffective treatment or adverse events of treatment. In this chapter, an overview of applicable PET tracers for the therapy response assessment in GB and the determination of tumor recurrence versus treatment-related effects is given.

show abstract

“…Also, when FET-PET was compared directly with MET-PET in 42 patients with gliomas or brain metastases, the 2 imaging agents provided comparable diagnostic information. 113 FDOPA-PET also was compared with MET-PET in patients with primary brain tumors or brain metastases and, similarly, yielded comparable diagnostic information. 114 FACBC has been studied primarily in prostate cancer, in which it had higher sensitivity for tumor detection compared with 111 In-capromab pendetide (Prostascint) and 11 C-choline.…”

Section: Imaging Protein and Cell Membrane Metabolismmentioning

confidence: 99%

PET/CT imaging in cancer: Current applications and future directions

Farwell

Pryma

Mankoff

2014

Cancer

191

125

View full text Add to dashboard Cite

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F-fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor-specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433-45.

show abstract

An Interindividual Comparison of O-(2- [18F]Fluoroethyl)-L-Tyrosine (FET)– and L-[Methyl-11C]Methionine (MET)–PET in Patients With Brain Gliomas and Metastases

Cited by 224 publications

References 25 publications

¹⁸F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis

¹⁸F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis

PET for Therapy Response Assessment in Glioblastoma

PET/CT imaging in cancer: Current applications and future directions

Contact Info

Product

Resources

About

An Interindividual Comparison of O-(2- [18F]Fluoroethyl)-L-Tyrosine (FET)– and L-[Methyl-11C]Methionine (MET)–PET in Patients With Brain Gliomas and Metastases

Cited by 224 publications

References 25 publications

18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis

18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis

PET for Therapy Response Assessment in Glioblastoma

PET/CT imaging in cancer: Current applications and future directions

Contact Info

Product

Resources

About

¹⁸F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis

¹⁸F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis